منابع مشابه
Teriflunomide slows BVL in relapsing MS
Objective: To assess, using structural image evaluation using normalization of atrophy (SIENA), the effect of teriflunomide, a once-daily oral immunomodulator, on brain volume loss (BVL) in patients with relapsing forms of MS enrolled in the phase 3 TEMSO study. Methods: TEMSO MR scans were analyzed (study personnel masked to treatment allocation) using SIENA to assess brain volume changes betw...
متن کاملTeriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first clinical demyelinating event. This review examines the EU SmPC for teriflunomide,...
متن کاملAssessing the Comparative Outcomes from Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of "Number Needed to Treat" Analysis.
1University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4Genzyme, a Sanofi company, Chilly-Mazarin, France; 5Comprehensive Multiple Sclerosis Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA P...
متن کاملRandomized trial of oral teriflunomide for relapsing multiple sclerosis.
BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the previous year or at least two relapses in the previous 2 years. Patients were ...
متن کاملTeriflunomide treatment reduces B cells in patients with MS
OBJECTIVE To study the immunomodulatory effect of teriflunomide on innate and adaptive immune cell populations through a pilot, open-label, observational study in a cohort of patients with relapsing-remitting MS. METHODS Blood lymphocytes were isolated from 10 patients with MS before and after 3 or 12 months of treatment. Adaptive and innate immune cell subsets were analyzed by flow cytometry...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology - Neuroimmunology Neuroinflammation
سال: 2017
ISSN: 2332-7812
DOI: 10.1212/nxi.0000000000000390